Design of greener drugs: aligning parameters in pharmaceutical R&D and drivers for environmental impact

被引:6
作者
Vidaurre, Rodrigo [1 ]
Bramke, Irene [2 ]
Puhlmann, Neele [3 ]
Owen, Stewart F. [4 ]
Angst, Daniela [5 ]
Moermond, Caroline [6 ]
Venhuis, Bastiaan [7 ]
Lombardo, Anna [8 ]
Kammerer, Klaus [3 ]
Sikanen, Tiina [9 ]
Ryan, Jim [1 ,10 ]
Haener, Andreas [1 ,11 ]
Janer, Gemma [1 ,2 ,12 ]
Roggo, Silvio [5 ]
Perkins, Alison Nimrod [1 ,3 ,13 ]
机构
[1] Ecol Inst gGmbH, Berlin, Germany
[2] AstraZeneca BV, The Hague, Netherlands
[3] Leuphana Univ Luneburg, Inst Sustainable Chem, Luneburg, Germany
[4] AstraZeneca, Macclesfield, England
[5] Novartis Pharm AG, Biomed Res, Basel, Switzerland
[6] Natl Inst PublicHealth & Environm RIVM, Ctr Safety Subst & Prod, Bilthoven, Netherlands
[7] Natl Inst Publ Hlth & Environm RIVM, Ctr Hlth Protect, Bilthoven, Netherlands
[8] Ist Ric Farmacol Mario Negri IRCSS, Dept Environm Hlth Sci, Lab Environm Toxicol & Chem, Milan, Italy
[9] Univ Helsinki, Fac Pharm, Drug Res Program, Helsinki, Finland
[10] GSK, EHSS Shared Serv, Stevenage, England
[11] F Hoffmann La Roche Ltd, Grp Safety, Secur Hlth & Environm Protect SHE, Basel, Switzerland
[12] Novartis Pharm, Global HSE, Barcelona, Spain
[13] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN USA
基金
欧盟地平线“2020”;
关键词
persistence; bioaccumulation; ecotoxicity; chemical mobility; safe and sustainable by design SSbD; environmentally benign; human health; BIOCONCENTRATION FACTORS; CONSERVATION; TARGETS; MODEL; RULE; FISH;
D O I
10.1016/j.drudis.2024.104022
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Active pharmaceutical ingredients (APIs) in the environment, primarily resulting from patient excretion, are of concern because of potential risks to wildlife. This has led to more restrictive regulatory policies. Here, we discuss the 'benign -by -design ' approach, which encourages the development of environmentally friendly APIs that are also safe and ef ficacious for patients. We explore the challenges and opportunities associated with identifying chemical properties that in fluence the environmental impact of APIs. Although a straightforward application of greener properties could hinder the development of new drugs, more nuanced approaches could lead to drugs that bene fit both patients and the environment. We advocate for an enhanced dialogue between research and development (R&D) and environmental scientists and development of a toolbox to incorporate environmental sustainability in drug development.
引用
收藏
页数:10
相关论文
共 48 条
  • [1] acs, ACS Green Chemistry
  • [2] Green Chemistry: Principles and Practice
    Anastas, Paul
    Eghbali, Nicolas
    [J]. CHEMICAL SOCIETY REVIEWS, 2010, 39 (01) : 301 - 312
  • [3] [Anonymous], Estimation Programs Interface Suite for Microsoft Windows
  • [4] Designing small molecules for biodegradability
    Boethling, R. S.
    Sommer, Elizabeth
    DiFiore, David
    [J]. CHEMICAL REVIEWS, 2007, 107 (06) : 2207 - 2227
  • [6] Ototoxin-induced cellular damage in neuromasts disrupts lateral line function in larval zebrafish
    Buck, Lauren M. J.
    Winter, Matthew J.
    Redfern, William S.
    Whitfield, Tanya T.
    [J]. HEARING RESEARCH, 2012, 284 (1-2) : 67 - 81
  • [7] A rule of three for fragment-based lead discovery?
    Congreve, M
    Carr, R
    Murray, C
    Jhoti, H
    [J]. DRUG DISCOVERY TODAY, 2003, 8 (19) : 876 - 877
  • [8] PHARMACEUTICALS IN THE ENVIRONMENT-GLOBAL OCCURRENCES AND PERSPECTIVES
    der Beek, Tim Aus
    Weber, Frank-Andreas
    Bergmann, Axel
    Hickmann, Silke
    Ebert, Ina
    Hein, Arne
    Kuester, Anette
    [J]. ENVIRONMENTAL TOXICOLOGY AND CHEMISTRY, 2016, 35 (04) : 823 - 835
  • [9] Ebert I, 2015, Pharmaceuticals in the environment - avoidance, reduction and monitoring
  • [10] European Commission, A Pharmaceutical Strategy for Europe